PE02002013A1 - pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol - Google Patents

pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol

Info

Publication number
PE02002013A1
PE02002013A1 PE2012002027A PE0020272012A PE02002013A1 PE 02002013 A1 PE02002013 A1 PE 02002013A1 PE 2012002027 A PE2012002027 A PE 2012002027A PE 0020272012 A PE0020272012 A PE 0020272012A PE 02002013 A1 PE02002013 A1 PE 02002013A1
Authority
PE
Peru
Prior art keywords
receptor agonist
composition
pharmaceutical composition
composition containing
sugar alcohol
Prior art date
Application number
PE2012002027A
Other languages
Spanish (es)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US46121503P priority Critical
Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE02002013(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of PE02002013A1 publication Critical patent/PE02002013A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN AGONISTA DEL RECEPTOR DE FOSFATO DE ESFINGOSINA-1 (S1P) TAL COMO 2-AMINO-2-[2-(4-OCTILFENIL)ETIL]PROPANO-1,3-DIOL (FTY720) QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.01% A 20% EN PESO DE LA COMPOSICION; Refers to a pharmaceutical composition containing: a) receptor agonist PHOSPHATE sphingosine-1 (S1P) AS 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol ( FTY720) found in an amount from 0.01% to 20% by weight of the composition; B) MANITOL QUE SE ENCUENTRA EN UNA CANTIDAD DE 75% A 99.5% EN PESO DE LA COMPOSICION; B) THAT MANITOL in an amount from 75% to 99.5% by weight of the composition; YC) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.01% A 5% EN PESO DE LA COMPOSICION. C) a lubricant such as magnesium stearate FOUND IN AN AMOUNT OF 0.01% to 5% by weight of the composition. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. Also it refers to a preparation process. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE UN RECHAZO AL TRANSPLANTE DE UN ORGANO O TEJIDO, ENFERMEDADES AUTOINMUNES, ARTRITIS Said composition is useful in the treatment of transplantation rejection organ or tissue, autoimmune diseases, arthritis
PE2012002027A 2003-04-08 2004-04-06 pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol PE02002013A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US46121503P true 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
PE02002013A1 true PE02002013A1 (en) 2013-03-09

Family

ID=32326722

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2008001684A PE07432009A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol
PE2013000382A PE13522013A1 (en) 2003-04-08 2004-04-06 pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol
PE2015000303A PE06762015A1 (en) 2003-04-08 2004-04-06 pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol
PE2012002027A PE02002013A1 (en) 2003-04-08 2004-04-06 pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol
PE2004000355A PE03962005A1 (en) 2003-04-08 2004-04-06 Solid pharmaceutical composition comprising a S1P receptor agonist and a sugar alcohol

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PE2008001684A PE07432009A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol
PE2013000382A PE13522013A1 (en) 2003-04-08 2004-04-06 pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol
PE2015000303A PE06762015A1 (en) 2003-04-08 2004-04-06 pharmaceutical composition containing a S1P receptor agonist and a sugar alcohol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2004000355A PE03962005A1 (en) 2003-04-08 2004-04-06 Solid pharmaceutical composition comprising a S1P receptor agonist and a sugar alcohol

Country Status (43)

Country Link
US (9) US20060275357A1 (en)
EP (5) EP2008650A3 (en)
JP (3) JP5495467B2 (en)
KR (3) KR20110005320A (en)
CN (2) CN101797241B (en)
AR (3) AR043987A1 (en)
AT (3) AT501681B1 (en)
AU (1) AU2004228929B2 (en)
BE (1) BE1015972A5 (en)
BR (1) BRPI0409250A (en)
CA (2) CA2707750A1 (en)
CL (2) CL2004000745A1 (en)
CY (2) CY1110260T1 (en)
DE (4) DE202004021680U1 (en)
DK (2) DK2316431T3 (en)
EC (1) ECSP056090A (en)
ES (3) ES2556947T3 (en)
FR (1) FR2854073B1 (en)
GB (1) GB2400318B (en)
GR (1) GR1005052B (en)
HK (3) HK1071685A1 (en)
HR (3) HRP20050886B1 (en)
HU (2) HUE028247T2 (en)
IE (1) IE20040246A1 (en)
IL (3) IL170888A (en)
IS (2) IS2682B (en)
IT (1) ITMI20040682A1 (en)
LU (1) LU91867I9 (en)
MA (1) MA27729A1 (en)
MX (1) MXPA05010860A (en)
MY (1) MY141249A (en)
NO (4) NO329332B1 (en)
NZ (3) NZ586280A (en)
PE (5) PE07432009A1 (en)
PL (2) PL1613288T3 (en)
PT (1) PT1613288E (en)
RU (5) RU2358716C2 (en)
SG (1) SG175449A1 (en)
SI (2) SI1613288T1 (en)
TN (1) TNSN05256A1 (en)
TW (1) TWI332847B (en)
WO (1) WO2004089341A1 (en)
ZA (1) ZA200507394B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993115B (en) * 2004-07-30 2011-12-28 诺瓦提斯公司 Formulation 2-amino-1,3-propanediol compound
CN1891212B (en) 2005-07-07 2010-10-13 马启明 Oral preparation and its preparing method
SI2295049T1 (en) * 2005-09-09 2015-03-31 Novartis Ag Treatment of autoimmune diseases
KR20080070049A (en) 2005-11-09 2008-07-29 프로테올릭스, 인코퍼레이티드 Compounds for enzyme inhibition
TWI389683B (en) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP5226679B2 (en) 2006-06-19 2013-07-03 プロテオリックス, インコーポレイテッド Compounds for enzyme inhibition
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
CA2953372A1 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical composition comprising an s1p receptor modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
BRPI0809205B1 (en) 2007-03-29 2019-09-03 Daiichi Sankyo Co Ltd pharmaceutical composition
US8367617B2 (en) 2007-10-04 2013-02-05 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
ES2545361T3 (en) * 2007-10-12 2015-09-10 Novartis Ag Compositions comprising sphingosine 1-phosphate (S1P) receptor modulators
JP5534645B2 (en) * 2008-01-11 2014-07-02 日医工株式会社 Oral dosage formulation containing sarpogrelate hydrochloride with excellent stability in an unwrapped state
JP5452237B2 (en) 2008-02-07 2014-03-26 杏林製薬株式会社 Therapeutic or prophylactic agent for inflammatory bowel disease comprising an amino alcohol derivative as an active ingredient
HUE033168T2 (en) 2008-03-17 2017-11-28 Actelion Pharmaceuticals Ltd Dosing regimen for a selective sip1 receptor agonist
RU2562571C2 (en) 2008-06-20 2015-09-10 Новартис Аг Paediatric compositions for treating multiple sclerosis
CA2728436C (en) * 2008-06-20 2016-07-26 Merck Patent Gmbh Directly compressible and rapidly disintegrating tablet matrix
BRPI0919183A2 (en) * 2008-09-04 2015-08-18 Cargill Inc Production of erythritol tablets.
ES2617560T3 (en) 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combination of the carfilzomib peptide epoxy ketone proteasome inhibitor with melphalan for use in the treatment of multiple myeloma
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
MX2011004924A (en) 2008-11-11 2011-05-30 Novartis Ag Salts of fingolimod.
EP2356090B1 (en) * 2008-11-11 2017-07-05 Novartis AG Crystalline forms of fingolimod hcl
WO2010071121A1 (en) 2008-12-17 2010-06-24 第一三共株式会社 Method for producing diamine derivative
WO2010082531A1 (en) 2009-01-13 2010-07-22 第一三共株式会社 Active blood coagulation factor inhibitor
ES2542236T3 (en) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Production process of a diamine derivative
CN102348680B (en) 2009-03-13 2014-11-05 第一三共株式会社 Method for producing optically active diamine derivative
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
ES2605034T3 (en) * 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited pharmaceutical composition with improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (en) 2009-11-13 2016-05-18 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. Use of peptide epoxy ketones for metastasis inhibition
SG183843A1 (en) 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
CA2793413C (en) 2010-03-19 2015-11-24 Daiichi Sankyo Company, Limited Crystal form of edoxaban tosylate monohydrate and method of producing same
KR101792299B1 (en) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 Method for improving dissolution of anticoagulant agent
US20130095177A1 (en) * 2010-04-22 2013-04-18 Ratiopharm Gmbh Method of preparing an oral dosage form comprising fingolimod
CN103080078B (en) 2010-07-02 2015-02-11 第一三共株式会社 Process for preparation of optically active diamine derivative salt
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
JO3177B1 (en) 2011-04-01 2018-03-08 Novartis Ag Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
EP2739272A1 (en) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
TWI578988B (en) 2011-08-10 2017-04-21 第一三共股份有限公司 Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (en) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Pharmaceutical composition of s1p receptor agonist for treatment of demyelinating diseases (versions) and method of its obtaining
RU2506949C1 (en) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Pharmaceutical composition of sip receptor agonist for treating demyeliniating diseases
EP2869820A4 (en) 2012-07-09 2016-02-17 Onyx Therapeutics Inc Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (en) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Pharmaceutical composition exhibiting improved flowability, drug preparation, method for preparing and using
EP2943189A4 (en) 2013-01-08 2016-07-06 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
MX2015015681A (en) * 2013-05-13 2016-03-15 Synthon Bv Pharmaceutical composition comprising fingolimod.
EP3027174B1 (en) * 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (en) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Pharmaceutical composition of s1p receptor agonist for treating demyeliniating diseases
CN106794159A (en) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2577230C1 (en) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Method of producing capsules of fingolimod hydrochloride
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (en) * 1976-07-12 1978-01-16 Akzo Nv A process for the preparation of novel peptides and peptide derivatives and the use thereof.
US4110332A (en) 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (en) * 1990-11-29 1998-12-24 田辺製薬株式会社 Long-term stable oral pharmaceutical formulations
KR0155015B1 (en) 1992-10-21 1998-12-01 고우야 마사시 2-amino-1,3-propanediol compound and immunosuppressant
DE69524962T4 (en) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp Benzene derivatives and their medical use
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (en) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp Medicinal composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4153563B2 (en) * 1997-02-27 2008-09-24 ノバルティス アーゲー Pharmaceutical composition
IL132208A (en) * 1997-04-04 2003-07-31 Mitsubishi Pharma Corp 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd New immunosuppressant, its use and its identification
JPH11209277A (en) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd Pharmaceutical composition
JP3545595B2 (en) 1998-04-01 2004-07-21 花王株式会社 The process of glycosphingolipid
JP4627356B2 (en) * 1999-06-30 2011-02-09 松森  昭 Drugs for preventing or treating viral myocarditis
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate
CN1267429C (en) 2000-07-13 2006-08-02 三共株式会社 Amino alcohol derivatives
EP1315735A4 (en) * 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
IL157773D0 (en) 2001-03-26 2004-03-28 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (en) 2001-04-20 2002-10-31 Sankyo Co Ltd Benzothiophene derivative
WO2003020313A1 (en) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
DE60223699T2 (en) 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfide derivative, the additional salt and immunosuppressive
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect

Also Published As

Publication number Publication date
US20140011885A1 (en) 2014-01-09
ES2320767T3 (en) 2009-05-28
AR078782A2 (en) 2011-11-30
NZ592339A (en) 2012-09-28
US20110105620A1 (en) 2011-05-05
HRP20050886B1 (en) 2011-01-31
IS2682B (en) 2010-10-15
RU2358716C2 (en) 2009-06-20
AU2004228929B2 (en) 2008-02-07
EP1613288B1 (en) 2008-11-19
US20080311188A1 (en) 2008-12-18
SI2316431T1 (en) 2016-04-29
TNSN05256A1 (en) 2007-07-10
GB2400318B (en) 2005-08-10
NZ542622A (en) 2009-01-31
MXPA05010860A (en) 2006-05-25
PE07432009A1 (en) 2009-07-17
CN101797241A (en) 2010-08-11
IL197578A (en) 2015-10-29
EP2769713A1 (en) 2014-08-27
KR20050121712A (en) 2005-12-27
PE13522013A1 (en) 2013-11-14
TW200503784A (en) 2005-02-01
JP5495467B2 (en) 2014-05-21
GR20040100121A (en) 2004-12-17
EP2008650A2 (en) 2008-12-31
KR20120101148A (en) 2012-09-12
FR2854073B1 (en) 2008-03-14
DE122011100047I1 (en) 2011-12-15
LU91867I2 (en) 2011-11-08
JP2004307506A (en) 2004-11-04
AR043987A1 (en) 2005-08-17
JP2013177404A (en) 2013-09-09
HK1091114A1 (en) 2009-06-26
LU91867I9 (en) 2019-01-03
DK2316431T3 (en) 2016-01-11
US20060275357A1 (en) 2006-12-07
NO334116B1 (en) 2013-12-16
CA2521325A1 (en) 2004-10-21
IE20040246A1 (en) 2004-12-15
DK1613288T3 (en) 2009-03-23
MY141249A (en) 2010-03-31
GB0407819D0 (en) 2004-05-12
FR2854073A1 (en) 2004-10-29
EP2319502A1 (en) 2011-05-11
NO20055231D0 (en) 2005-11-07
SG175449A1 (en) 2011-11-28
IL242037D0 (en) 2015-11-30
BRPI0409250A (en) 2006-03-28
US20090203798A1 (en) 2009-08-13
US20190175527A1 (en) 2019-06-13
GB2400318A (en) 2004-10-13
ES2556947T3 (en) 2016-01-21
AT414508T (en) 2008-12-15
NO20100250L (en) 2006-01-09
EP2316431B1 (en) 2015-09-30
US8324283B2 (en) 2012-12-04
HRP20100601A2 (en) 2011-03-31
DE602004017847D1 (en) 2009-01-02
GR1005052B (en) 2005-11-30
AT504853A2 (en) 2008-08-15
SI1613288T1 (en) 2009-04-30
AT501681A1 (en) 2006-10-15
EP2316431A1 (en) 2011-05-04
HK1155647A1 (en) 2016-03-24
KR101367574B1 (en) 2014-02-25
AT501681B1 (en) 2012-04-15
CL2004000745A1 (en) 2005-02-11
IL170888A (en) 2010-06-16
KR20110005320A (en) 2011-01-17
RU2010146697A (en) 2012-05-27
NO20055231L (en) 2006-01-09
PL2316431T3 (en) 2016-09-30
CY1110260T1 (en) 2014-04-09
US20140255497A1 (en) 2014-09-11
PT1613288E (en) 2009-02-25
CA2707750A1 (en) 2004-10-21
RU2005134173A (en) 2006-09-10
RU2010147000A (en) 2012-08-10
CA2521325C (en) 2010-09-14
EP2008650A3 (en) 2011-04-27
NO20131287L (en) 2006-01-09
WO2004089341A1 (en) 2004-10-21
RU2012148593A (en) 2014-05-20
DE202004021680U1 (en) 2010-04-22
IS8114A (en) 2005-11-01
JP5543298B2 (en) 2014-07-09
EP1613288A1 (en) 2006-01-11
JP2011006461A (en) 2011-01-13
HK1071685A1 (en) 2006-08-04
HRP20100601B1 (en) 2016-12-02
NO335120B1 (en) 2014-09-22
AR078781A2 (en) 2011-11-30
MA27729A1 (en) 2006-01-02
CN101797241B (en) 2013-03-27
HRP20050886A2 (en) 2006-11-30
ITMI20040682A1 (en) 2004-07-06
IS8885A (en) 2010-02-25
HRP20100600A2 (en) 2011-03-31
NO2011016I2 (en) 2012-08-27
US20130108675A1 (en) 2013-05-02
NO329332B1 (en) 2010-09-27
NZ586280A (en) 2011-12-22
CN1767819A (en) 2006-05-03
RU2475236C2 (en) 2013-02-20
ES2228282A1 (en) 2005-04-01
LU91867A9 (en)
ES2228282B1 (en) 2006-02-16
DE102004016947A1 (en) 2004-10-21
AU2004228929A1 (en) 2004-10-21
IL197578D0 (en) 2011-07-31
RU2009105403A (en) 2010-08-27
ZA200507394B (en) 2007-03-28
HUS1100016I1 (en) 2016-08-29
NO2011016I1 (en) 2011-09-19
CY1117071T1 (en) 2017-04-05
BE1015972A5 (en) 2005-12-06
CL2011000450A1 (en) 2011-11-25
US20170290787A1 (en) 2017-10-12
PL1613288T3 (en) 2009-07-31
PE06762015A1 (en) 2015-05-17
TWI332847B (en) 2010-11-11
RU2475237C2 (en) 2013-02-20
ECSP056090A (en) 2006-03-01
CN1767819B (en) 2010-07-28
HUE028247T2 (en) 2016-12-28
PE03962005A1 (en) 2005-07-05

Similar Documents

Publication Publication Date Title
CN101600438B (en) Therapeutic agent for pain disease
ECSP12011834A (en) pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for their treatment and their uses.
GT200500384A (en) Forms of solid pharmaceutical dosage administrable orally with modified release
GT200400126A (en) Compounds antiperspirant active aluminum / zirconium / glycine betaine stabilized
CL2007001166A1 (en) pyrimidine derivatives condensed compounds, inhibitors of PI3K; processes for preparing the compounds; pharmaceutical composition that comprises; use of the compounds in the preparation of medicines; process for preparing the pharmaceutical composition; and kit that includes the pharmaceutical composition
CL2009001059A1 (en) Compounds derived from 1,3-oxazin-2-one 3,6-substituted, inhibitors of the activity of 11-beta-hydroxysteroid dehydrogenase i; pharmaceutical composition that comprises; useful in treating diseases such as diabetes mellitus, among others.
UY31080A1 (en) Substituted pyrazole derivatives useful for treating hyperproliferative disorders heteroaryl and diseases associated with angiogenesis
CL2011000450A1 (en) Process for preparing a pharmaceutical composition comprising a) mixing an S1P receptor agonist selected from 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol and a salt thereof with a sugar alcohol; b) milling and / or granulating the mixture; c) blending the mixture with a lubricant (divisional application 745-2004).
AR061968A1 (en) Acid isopropyl ester 4- [5-methoxy-6- (2-methyl-6- [1,2,4] triazol-i-yl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine -i-carboxylic acid, pharmaceutical composition comprising the same and a preparation method thereof and the use of this compound for the treatment of metabolic disorders
MA33593B1 (en) Heterocyclic compounds and their uses
CO6460769A2 (en) Inhibitors novel viral replication
ES2146300T3 (en) Use of anthelmintic compositions for the treatment of infections caused by Anoplocephala perfoliata in horses.
NO341617B1 (en) Dihydropyrazolpyrimidinonderivater, their use in therapy and in the treatment of cancer, their use for the preparation of a medicament, and for use as strålingssensibilisator pharmaceutical composition thereof, as well as a combined preparation for administration in the treatment of cancer.
UY31295A1 (en) pharmaceutical composition comprising an SGLT2
HRP20070043A2 (en) Antiviral compounds
UY33735A (en) antiviral compounds
PE04642006A1 (en) pharmaceutical composition comprising flibanserin for the treatment of sexual disorders
CR9662A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
NO329107B1 (en) C-arylglucoside, pharmaceutical compositions containing them and to the use thereof for preparing medicaments for treating disease
CR20140313A (en) Biaryl ether urea compounds
BR0315720A (en) A compound, method for the prophylaxis or treatment of a clinical condition in a mamìmefero, pharmaceutical composition, combination use of a compound, a process for the preparation of a compound and intermediate
UY28564A1 (en) Chemical compounds
MA34727B1 (en) Imidazolylimidazoles condensed used as antiviral compounds
MA32887B1 (en) Aminotetrahydropyranes as inhibitors of dipeptidyl peptidase-IV for the treatment or prevention of diabetes
ECSP11011277A (en) A pharmaceutical composition comprising an SGLT2 inhibitor, an inhibitor of DPPIV and optionally an antidiabetic agent, and their uses.

Legal Events

Date Code Title Description
FC Refusal